202 related articles for article (PubMed ID: 15720212)
1. Huntington's disease: new frontiers for molecular and cell therapy.
Melone MA; Jori FP; Peluso G
Curr Drug Targets; 2005 Feb; 6(1):43-56. PubMed ID: 15720212
[TBL] [Abstract][Full Text] [Related]
2. Huntington's disease: an update of therapeutic strategies.
Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
[TBL] [Abstract][Full Text] [Related]
3. Cell therapy in Huntington's disease.
Dunnett SB; Rosser AE
NeuroRx; 2004 Oct; 1(4):394-405. PubMed ID: 15717043
[TBL] [Abstract][Full Text] [Related]
4. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
5. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
Podvin S; Reardon HT; Yin K; Mosier C; Hook V
J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
[TBL] [Abstract][Full Text] [Related]
6. Cell Replacement Therapy for Huntington's Disease.
Monk R; Connor B
Adv Exp Med Biol; 2020; 1266():57-69. PubMed ID: 33105495
[TBL] [Abstract][Full Text] [Related]
7. Cellular therapy and induced neuronal replacement for Huntington's disease.
Benraiss A; Goldman SA
Neurotherapeutics; 2011 Oct; 8(4):577-90. PubMed ID: 21971961
[TBL] [Abstract][Full Text] [Related]
8. Huntington's disease and cell therapies: past, present, and future.
Antoniades CA; Watts C
Methods Mol Biol; 2013; 1010():19-32. PubMed ID: 23754216
[TBL] [Abstract][Full Text] [Related]
9. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
10. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
11. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
12. Deterioration of neuroregenerative plasticity in association with testicular atrophy and dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis in Huntington's disease: A putative role of the huntingtin gene in steroidogenesis.
Selvaraj K; Manickam N; Kumaran E; Thangadurai K; Elumalai G; Sekar A; Radhakrishnan RK; Kandasamy M
J Steroid Biochem Mol Biol; 2020 Mar; 197():105526. PubMed ID: 31715317
[TBL] [Abstract][Full Text] [Related]
13. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
[TBL] [Abstract][Full Text] [Related]
14. Huntington's disease: pathological mechanisms and therapeutic strategies.
Ramaswamy S; Shannon KM; Kordower JH
Cell Transplant; 2007; 16(3):301-12. PubMed ID: 17503740
[TBL] [Abstract][Full Text] [Related]
15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
16. [Huntington disease. A review].
Bonilla E
Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Bithell A; Johnson R; Buckley NJ
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
[TBL] [Abstract][Full Text] [Related]
18. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
19. Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward.
Bachoud-Lévi AC; Massart R; Rosser A
Stem Cells; 2021 Feb; 39(2):144-155. PubMed ID: 33176057
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
